Company Profile

Avatar Biotechnologies LLC (AKA: Avatar Medical LLC)
Profile last edited on: 2/28/2020      CAGE: 5TNJ7      UEI: HQ61PQ64HFU4

Business Identifier: Improving vaccine immunogens performance
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

140 58th Street Building A Unit 8j
Brooklyn, NY 11220
Location: Single
Congr. District: 10
County: Kings

Public Profile

With funding from the Bill and Melinda Gates Foundation, in collaboration with the International AIDS Vaccine Initiative (IAVI), Avatar is a biotechnology company applying proprietary technologies to develop conformationally locked, improved sub-unit vaccine immunogens. The company’s technologies are designed to enhance the performance of these products by stabilizing their conformations, which then better represent the 3-D structure of these proteins on the surface of the pathogen, and therefore give rise to more protective antibody responses. Avatar has applied its di-tyrosine conformational locking approach to render feasible the production of vaccines that protect against key viral diseases that represent both significant unmet medical needs and blockbuster commercial opportunities. These are a universal Influenza vaccine, and a vaccine against Respiratory Syncytial Virus (RSV), a common pediatric infection. Both immunogens have been successfully conformationally stabilized with DT crosslinks and studies are underway in collaboration with opinion leaders at the NIH and academia to test them; expected to provide animal proof of principle.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2020 2 NIH $3,086,417
Project Title: A Universal Flu Vaccine Based on Conformationally Locked Soluble Headless HA
2017 2 NIH $2,193,656
Project Title: Dityrosine Locked Prefusion F Protein: a Path to a Protective RSV Vaccine
2015 2 NIH $3,590,132
Project Title: Conformational Stabilization of the HIV-1 ENV Trimer
2002 1 NIH $99,900
Project Title: Novel Lithographic Protein-Bioreceptor Immobilization

Key People / Management

  Christopher Marshall -- Founder,President andChief Executive Officer

  Claudio Bertuccioli -- VP Business Development & Finance

  Roberto Mariani

  Evgeny N Vulfson

  Mark Yondola

Company News

There are no news available.